Dr Reddys Laboratories Ltd Technical Momentum Shifts to Mildly Bullish Amid Mixed Indicators

Technical Trend Overview and Price Movement

The stock currently trades at ₹1,218.00, up 0.73% from the previous close of ₹1,209.20, with intraday highs reaching ₹1,222.15 and lows at ₹1,167.30. Despite this modest daily gain, the broader technical trend has shifted from mildly bearish to mildly bullish, signalling a potential change in momentum that investors should monitor closely.

Over the past week, Dr Reddys has underperformed the Sensex, with a stock return of -6.44% compared to the Sensex’s -2.60%. However, on a one-year horizon, the stock has outperformed significantly, delivering a 5.94% return against the Sensex’s -4.30%. This divergence highlights the stock’s resilience amid sectoral and market volatility.

MACD Signals: Bullish Weekly, Mildly Bearish Monthly

The Moving Average Convergence Divergence (MACD) indicator presents a nuanced picture. On a weekly basis, the MACD is bullish, suggesting upward momentum in the near term. This is a positive sign for traders looking for confirmation of a trend reversal or continuation. Conversely, the monthly MACD remains mildly bearish, indicating that longer-term momentum has yet to fully confirm a sustained uptrend. This divergence between weekly and monthly MACD readings suggests that while short-term sentiment is improving, caution remains warranted for longer-term investors.

RSI and Bollinger Bands: Neutral to Bearish Signals

The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in neutral territory. This implies that the stock is neither overbought nor oversold, providing a balanced backdrop for potential price moves. However, Bollinger Bands on both weekly and monthly timeframes remain bearish, indicating that price volatility is skewed towards downside risk. The stock’s price is likely trading near the lower band, which could act as a support level or signal potential for a rebound if momentum shifts.

Moving Averages and KST: Mildly Bullish Daily and Weekly

Daily moving averages have turned mildly bullish, reflecting recent price gains and suggesting that short-term momentum is improving. The KST (Know Sure Thing) indicator, which aggregates multiple rate-of-change measures, is bullish on a weekly basis but mildly bearish monthly. This mixed signal aligns with the MACD’s pattern, reinforcing the notion of short-term strength amid longer-term caution.

Volume and Dow Theory Perspectives

On-Balance Volume (OBV) is mildly bullish weekly, indicating that volume trends support recent price advances. However, monthly OBV shows no clear trend, which tempers enthusiasm for a sustained rally. Dow Theory assessments are mildly bearish weekly but mildly bullish monthly, further underscoring the transitional phase in the stock’s technical profile.

Comparative Returns and Market Capitalisation

Dr Reddys Laboratories is classified as a large-cap stock within the Pharmaceuticals & Biotechnology sector, carrying a Mojo Score of 64.0 and a current Mojo Grade of Hold, upgraded from Sell on 2 April 2026. This upgrade reflects improved technical and fundamental assessments by MarketsMOJO analysts.

Examining returns over various periods reveals a mixed but generally positive performance relative to the Sensex. While the stock has lagged the benchmark over the short term (1 week and 1 month), it has outperformed over the year-to-date and one-year periods, with returns of -4.17% YTD versus -13.96% for the Sensex, and 5.94% over one year compared to the Sensex’s -4.30%. Over three and five years, the stock has delivered 31.78% and 32.74% returns respectively, though these trail the Sensex’s 24.29% and 46.55% gains. The ten-year return of 104.37% is substantial but notably below the Sensex’s 190.15%, indicating room for long-term growth acceleration.

Technical Outlook and Investor Implications

The mild bullish shift in technical momentum suggests that Dr Reddys Laboratories may be entering a phase of consolidation or moderate recovery after a period of weakness. The weekly bullish MACD and KST indicators, combined with mildly bullish daily moving averages and OBV, support the case for cautious optimism among traders and investors.

However, the persistence of bearish signals from Bollinger Bands and monthly MACD, alongside neutral RSI readings, advises prudence. Investors should watch for confirmation of trend strength through sustained price moves above key resistance levels, such as the recent intraday high of ₹1,222.15 and the 52-week high of ₹1,377.95.

Given the stock’s mixed technical signals and recent upgrade to a Hold rating, a balanced approach is recommended. Investors may consider accumulating on dips with tight stop-losses or await clearer confirmation of a sustained uptrend before increasing exposure.

Summary

Dr Reddys Laboratories Ltd is currently navigating a transitional phase in its technical profile, with short-term indicators turning mildly bullish while longer-term signals remain cautious. The recent upgrade from Sell to Hold by MarketsMOJO reflects this evolving outlook. Investors should weigh the mixed signals carefully, considering both the stock’s relative outperformance over longer periods and its recent underperformance against the Sensex in the short term.

Monitoring key technical levels and volume trends will be critical in the coming weeks to ascertain whether the stock can sustain its upward momentum or if it will face renewed selling pressure. The pharmaceutical sector’s inherent volatility and regulatory environment also warrant attention as part of a comprehensive investment strategy.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today